Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
Zacks
More News
$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers
Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries.
Stocktwits
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.
Zacks
BioXcel Therapeutics Agrees To Teva Asset Sale
(RTTNews) - BioXcel Therapeutics Inc. (BTAI) on Friday entered into an agreement to sell substantially all of its assets to Teva Pharmaceuticals International GmbH (TEVA.TA) and filed for voluntary Chapter 11 bankruptcy...
Nasdaq News: Markets
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Zacks
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.
Zacks
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
Zacks
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.
Zacks
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.
Zacks
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.